Cover Image
市場調查報告書

亨丁頓舞蹈症:主要8個國家的市場預測

Epiomic Epidemiology Series: Huntington's Disease Forecast in 8 Major Markets 2015-2025

出版商 Black Swan Analysis 商品編碼 339882
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
亨丁頓舞蹈症:主要8個國家的市場預測 Epiomic Epidemiology Series: Huntington's Disease Forecast in 8 Major Markets 2015-2025
出版日期: 2015年08月11日 內容資訊: 英文 36 Pages
簡介

亨丁頓舞蹈症是先天性、一般染色體顯性疾病,惡化會造成神經機能的惡化、障礙。中年期發病病例最多,此外年齡也與存活時間呈比例的趨勢。

本報告提供全球主要8個國家(美國,法國,德國,義大利,西班牙,英國,巴西,日本) 的亨丁頓舞蹈症發病情形相關分析,提供您疾病概要和目前的患病人數,障礙的按內容·重度及性別·各年代 (以五歲為區分) 的詳細情況,各地區·各民族趨勢,風險要素,疾病診斷與預後,主要的症狀和併發症,未來性的趨勢預測 (今後10年份) 等資訊,為您概述為以下內容。

目錄

  • 簡介
  • 疾病的原因
  • 風險要素與預防法
  • 疾病診斷
  • 各地區/各民族的差異
  • 疾病的預後與臨床經過
  • UHDRS (亨丁頓舞蹈症統一評估尺度)
  • 整體功能的能力
  • 分析方法
  • 亨丁頓舞蹈症的最大患病人數
  • 亨丁頓舞蹈症的患病人數:UHDRS的障礙的類別·病情明細
    • 整體功能的各能力階段明細
    • 運動功能障礙的患病人數
    • 行動障礙的患病人數
    • 認知障礙的患病人數
  • 參考文獻
  • 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HUND0010815

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Huntington's disease in 8 Major Markets

Presented in an easy to understand table format, this report provides the current prevalent population for Huntington's disease across 8 Major Markets (USA, France, Germany, Italy, Spain, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides a 10-year forecast projection based on population trends in each of the major markets. The report also contains a disease overview including risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Huntington's patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Huntington's disease include:

  • Total functional capacity by stage
  • Nervous system dysfunction
  • Psychiatric disorders
  • Cognitive disorders
  • Major depressive disorder
  • Personality changes
  • Anxiety disorders
  • Nocturia
  • Moderate / Severe Sleep disturbance

The report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Table of Contents

  • List of Tables & Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis &Clinical Course
  • Unified Huntington's Disease Rating Scale (UHDRS)
  • Total Functional Capacity
  • Methodology
  • Top-Line Huntington's Disease Prevalence
  • Prevalence of UHDRS Components within the Huntington's Disease Cohort
    • Total Functional Capacity Stage Breakdown
    • Prevalence of Motor Dysfunction in Huntington's Patients
    • Prevalence of Behavioural Dysfunction in Huntington's Patients
    • Prevalence of Cognitive dysfunction in Huntington's Patients
  • References
  • Appendix

List of Tables & Figures

  • Total functional capacity scores and stages
  • Prevalence of Huntington's Disease, total (000s)
  • Prevalence of Huntington's Disease, males (000s)
  • Prevalence of Huntington's Disease, females (000s)
  • Huntington's Disease by TFC stage (000s)
  • Huntington's Disease patients with autonomic nervous system dysfunction (000s)
  • Huntington's Disease patients with psychiatric disorders (000s)
  • Huntington's Disease patients with major depressive disorder (000s)
  • Huntington's Disease patients with personality changes (000s)
  • Huntington's Disease patients with any anxiety disorder (000s)
  • Huntington's Disease patients with cognitive disorders (000s)
  • Huntington's Disease patients with nocturia (000s)
  • Huntington's Disease patients with moderate o severe sleep disturbance (000s)
  • USA Prevalence of Huntington's by 5-yr age cohort, males (000s)
  • USA Prevalence of Huntington's by 5-yr age cohort, females (000s)
  • France Prevalence of Huntington's by 5-yr age cohort, males (000s)
  • France Prevalence of Huntington's by 5-yr age cohort, females (000s)
  • Germany Prevalence of Huntington's by 5-yr age cohort, males (000s)
  • Germany Prevalence of Huntington's by 5-yr age cohort, females (000s)
  • Italy Prevalence of Huntington's by 5-yr age cohort, males (000s)
  • Italy Prevalence of Huntington's by 5-yr age cohort, females (000s)
  • Spain Prevalence of Huntington's by 5-yr age cohort, males (000s)
  • Spain Prevalence of Huntington's by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Huntington's by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Huntington's by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Huntington's by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Huntington's by 5-yr age cohort, females (000s)
  • Japan Prevalence of Huntington's by 5-yr age cohort, males (000s)
  • Japan Prevalence of Huntington's by 5-yr age cohort, females (000s)
Back to Top